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Previous studies using a rat 5-choice serial reaction time task have established a critical
role for dopamine D2 receptors in regulating increments in motor impulsivity induced by
acute administration of the psychostimulant drugs amphetamine and nicotine. Here we
investigated whether cannabinoid CB1 and/or μ-opioid receptors are involved in nicotine-
induced impulsivity, given recent ﬁndings indicating that both receptor systems mediate
amphetamine-induced motor impulsivity. Results showed that the cannabinoid CB1 recep-
tor antagonist SR141716A, but not the opioid receptor antagonist naloxone, reduced
nicotine-induced premature responding, indicating that nicotine-induced motor impulsivity
is cannabinoid, but not opioid receptor-dependent. In contrast, SR141716A did not affect
impulsivity following a challenge with the dopamine transporter inhibitor GBR 12909, a
form of drug-induced impulsivity that was previously found to be dependent on μ-opioid
receptor activation.Together, these data are consistent with the idea that the endogenous
cannabinoid, dopamine, and opioid systems each play important, but distinct roles in reg-
ulating (drug-induced) motor impulsivity. The rather complex interplay between these neu-
rotransmitter systems modulating impulsivity will be discussed in terms of the differential
involvement of mesocortical and mesolimbic neurocircuitry.
Keywords: 5-choice serial reaction time task, endocannabinoid system, endogenous opioid system, inhibitory
response control, mesocortical dopamine system, mesolimbic dopamine system, nicotine, rat
INTRODUCTION
Impulsivity is a multifaceted construct covering various, largely
independent, behavioral measures including inhibitory control
or motor impulsivity, i.e., the inability to restrain inappropri-
ate behavior (Evenden, 1999; Winstanley et al., 2006; Pattij and
Vanderschuren, 2008; Broos et al., 2012). There is considerable
evidence in human and rodent literature for a link between mal-
adaptive display of various types of impulsive behaviors and abuse
of/addiction to different classes of drugs of abuse. The direction
of this interaction is likely to be bidirectional, with heightened
levels of impulsivity predisposing individuals for display of addic-
tive behaviors and exposure to addictive substances increasing
display of impulsive behaviors (Jentsch and Taylor, 1999; Perry
and Carroll, 2008; Verdejo-Garcia et al., 2008; Winstanley et al.,
2010a). A common effect of acute administration of addictive sub-
stances such as psychostimulants, opiates, and alcohol in rodents
is an increase in motor impulsivity (Cole and Robbins, 1987; van
Gaalen et al., 2006; Olmstead et al., 2009; Pattij et al., 2009),
reﬂected in an increase in premature responding in, e.g., the 5-
choice serial reaction time task (5-CSRTT; Robbins, 2002). This
commonality between different types of drugs of abuse may be
related to their shared ability to increase dopamine release in the
brain (Di Chiara and Imperato, 1988; Sulzer, 2011). There are
three anatomically segregated, but heavily interacting dopamin-
ergic circuitries in the brain; the nigrostriatal, the mesolimbic,
and the mesocortical dopamine systems (Ungerstedt, 1971; Fal-
lon and Moore, 1978; Goto and Grace, 2007). Particularly the
mesolimbic and mesocortical systems, comprising projections
from the ventral tegmental area to respectively limbic structures
like the nucleus accumbens and frontal cortical areas, are thought
to regulate motor impulsivity in humans and rodents (Pattij and
Vanderschuren, 2008; Dalley et al., 2011;Winstanley, 2011). In this
respect,most studies on amphetamine-inducedmotor impulsivity
revealed an important role for the mesolimbic dopamine system,
andmore speciﬁcally dopamine signaling anddopamineD2 recep-
tor activity in the nucleus accumbens (Cole and Robbins, 1987,
1989; Pattij et al., 2007b).
Recently, other neurotransmitter systems have also been impli-
cated in amphetamine-induced motor impulsivity. For instance,
antagonists of the cannabinoid CB1 receptor and μ-opioid recep-
tor have been found to suppress the impulsivity-related effects of
amphetamine in the 5-CSRTT (Wiskerke et al., 2011a,b), possi-
bly via interactions with dopaminergic systems (Wiskerke et al.,
2011a; Kleijn et al., 2012). As to whether or not these cannabi-
noid and opioid mechanisms generalize to other drugs of abuse
remains to be determined. In this regard, the psychostimulant
drug nicotine is of particular interest. Tobacco smoking is a major
global health problem causing a large ﬁnancial burden for soci-
ety. There is a wealth of evidence from human and rodent studies
indicating a reciprocal link between impulsivity andnicotine abuse
(Bickel et al., 1999; Mitchell, 2004; Doran et al., 2007; Diergaarde
et al., 2008, 2011; Counotte et al., 2009). Acute challenges with
nicotine induce inhibitory control deﬁcits in the 5-CSRTT via
stimulation of nicotinic receptors, particularly α4β2-receptors in
www.frontiersin.org June 2012 | Volume 3 | Article 108 | 1
Wiskerke et al. Cannabinoids and opioids in impulsivity
the infralimbic cortex (Blondel et al., 2000; Grottick and Higgins,
2000; Tsutsui-Kimura et al., 2010). However, as for ampheta-
mine, nicotine-induced increments in motor impulsivity have
been reported to additionally depend on dopamine D2 recep-
tor and serotonin 5-HT2c receptor activity (van Gaalen et al.,
2006; Fletcher et al., 2011; Higgins et al., 2012). Thus, and since
there is ample evidence for an important role for cannabinoid
CB1 and μ-opioid receptors in other nicotine-induced behav-
iors (Berrendero et al., 2010; Hadjiconstantinou and Neff, 2011;
Serrano and Parsons, 2011), the aim of the current study was
to examine whether cannabinoid CB1 and μ-opioid receptors
mediate nicotine-induced motor impulsivity.
MATERIALS AND METHODS
SUBJECTS
Male Wistar rats were obtained from Harlan CPB (Horst,
The Netherlands). At the start of the experiments ani-
mals weighed approximately 250 grams, and were housed
two per cage in macrolon cages (42.5 cm× 26.6 cm× 18.5 cm;
length×width× height) under a reversed 12 h light/dark cycle
(lights on at 7.00pm) at controlled room temperature (21± 2˚C)
and relative humidity of 60± 15%. Animals were maintained at
approximately 90% of their free-feeding weight, starting 1week
prior to the beginning of the experiments by restricting the
amount of standard rodent food pellets (Harlan Teklad Global
Diet, Blackthorn, UK). Water was available ad libitum through-
out the entire experiment. All experiments were conducted with
the approval of the animal ethical committee of the VU Univer-
sity Amsterdam, The Netherlands, and all efforts were made to
minimize animal suffering.
DRUGS
SR141716A was generated and kindly provided by Abbott
(Weesp, The Netherlands) and dissolved in a mixture of
ethanol, Tween 80, and sterile saline (ratio 1:1:18). Nalox-
one hydrochloride, nicotine hydrogen tartrate, and S(−)-
eticlopride hydrochloride (all Sigma Aldrich, St. Louis, MO,
USA) were dissolved in sterile saline, whereby it should be
noted that the pH was neutralized for nicotine after dis-
solving the salt. 1-(2-[Bis(4-ﬂuorophenyl)methoxy]ethyl)-4-(3-
phenylpropyl) piperazine dihydrochloride (GBR 12909 dihy-
drochloride; Sigma Aldrich) was dissolved in sterile water. Drug
doses (calculated as salts) and injection times were based on pre-
vious 5-CSRTT studies in our laboratory (van Gaalen et al., 2006;
Pattij et al., 2007a, 2009;Wiskerke et al., 2011a,b). SR141716A was
injected 45min prior to testing, naloxone, and eticlopride 30min
prior to testing, and GBR 12909 and nicotine 20min prior to test-
ing. Drugs were freshly prepared on each test day and injected
intraperitoneally (i.p.), with an exception for nicotine which was
administered subcutaneously (s.c.), in a volume of 1ml/kg body-
weight according to a Latin square within subjects design. Drug
tests were conducted on Tuesdays and Fridays with baseline train-
ing sessions on the otherweekdays. Prior to the ﬁrst test day, all ani-
mals had been habituated twice to i.p. and/or s.c. saline injections.
APPARATUS
Experiments were conducted in identical rat ﬁve hole nose poke
operant chambers with stainless steel grid ﬂoors (MED-NPW-
5L, Med Associates Inc., St. Albans, VT, USA) housed in sound-
insulating and ventilated cubicles. Set in the curved wall of each
box was an array of ﬁve holes. Each nose poke unit was equipped
with an infrared detector and a yellow light emitting diode (LED)
stimulus light. Rodent food pellets (45mg, Formula P, Bio-Serv,
Frenchtown, NJ, USA) could be delivered at the opposite wall via
a dispenser. In addition, a white house light could illuminate the
chamber. A computer equipped with MED-PC version 1.17 (Med
Associates Inc.) controlled experimental sessions and recorded
data. Animals were tested once daily from Monday until Friday,
during the dark phase of the light/dark cycle.
BEHAVIORAL PROCEDURES
Separate groups of animals (n= 14–16) were trained for each
experiment involving a different drug (combination),unless stated
otherwise. Importantly, each rat was trained in the same operant
chamber for the entire experiment. Prior to the 5-CSRTT, animals
were subjected to habituation and magazine training protocols.
This protocol consisted of a habituation exposure to the operant
chambers for 20minwith the house light on and the food cup con-
taining three food pellets during the ﬁrst session. Subsequently, in
the next two sessions, in total 75 pellets were delivered with an
average delay of 15 s to allow the animals to associate the sound of
pellet delivery with reward.
5-CHOICE SERIAL REACTION TIME TASK
A detailed description of the 5-CSRTT behavioral procedure in
our laboratory has been provided previously (van Gaalen et al.,
2006). In short, rats were trained to detect and respond to a brief
visual stimulus in one of 5 nose poke units in order to obtain a
food reward. Each session terminated after 100 trials or 30min,
whichever occurred ﬁrst. Initially the duration of this stimulus
was 32 s and was gradually decreased to 1 s over sessions until ani-
mals reached stable baseline performance (accuracy>80% correct
choice and <20% errors of omission). Responding during stim-
ulus presentation or within the limited hold (LH) period of 2 s
was counted as a correct response. Incorrect responses, premature
responses during the ﬁxed 5 s intertrial interval (ITI), and errors
of omission (no response during stimulus presentation or sub-
sequent LH) did not lead to the delivery of a food reward and
resulted in a 5-s time-out period during which the house light was
extinguished. Importantly, when drug effects were studied under
conditions with lengthened ITI duration, only for those speciﬁc
test days, a ﬁxed 7 s ITI was used. Perseverative responses after
correct choice, i.e., repeated responding during stimulus presen-
tation into any stimulus unit following correct stimulus detection
and before pellet collection, were measured but did not have any
programmed consequences. The number of premature responses
was used as an index for inhibitory control. In addition, the fol-
lowing other behavioral parameters were measured that reﬂect
task performance: (1) accurate choice, i.e., percentage correct
responses calculated as [number correct trials/(correct+ incorrect
trials)]∗100; (2) omission errors, i.e., the total number of omitted
trials during a session and; (3) the total number of perseverative
responses after correct choice, measuring aspects of compulsive
behavior (Robbins, 2002); (4) latency to make a correct choice,
i.e., the mean time between stimulus onset and nose poke in the
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illuminated unit; and (5) feeder latency, i.e., the latency to collect
a pellet following correct choice.
STATISTICAL ANALYSES
All data were analyzed using NCSS2007 version 07.1.18 (NCSS,
LLC., Kaysville, UT, USA). Data were subjected to repeated mea-
sures analyses of variance (ANOVAs) with drug treatment as
within subjects variable, except for 5-CSRTT experiments involv-
ing lengthened ITI duration. In that case, data were subjected
to two-way ANOVAs with drug treatment and ITI duration as
within subjects variables.When appropriate, homogeneity of vari-
ance across groups was determined using Mauchly’s tests for
equal variances, and in case of violation of homogeneity, Huynh–
Feldt epsilon (ε) adjusted degrees of freedom were applied and
the resulting more conservative probability values depicted and
used for subsequent analyses. In case of statistically signiﬁcant
main effects, further post hoc comparisons were conducted using
Newman–Keuls multiple comparison tests. The level of probabil-
ity for statistically signiﬁcant effects was set at 0.05. All graphs
were produced using GraphPad Prism version 5.02 for Windows
(GraphPad Software, San Diego, CA, USA).
RESULTS
ENDOGENOUS CANNABINOIDS MODULATE NICOTINE-, BUT NOT GBR
12909-INDUCED MOTOR IMPULSIVITY
It has previously been shown that both the psychostimulants
amphetamine and nicotine induce increments in motor impul-
sivity in rats via a dopamine D2 and serotonin 5-HT2c receptor-
dependent mechanism (van Gaalen et al., 2006; Pattij et al.,
2007b; Fletcher et al., 2011; Higgins et al., 2012). Moreover,
amphetamine-induced premature responding in the 5-CSRTT
has been reported to be cannabinoid CB1 receptor-dependent
(Wiskerke et al., 2011b). Here we determined whether CB1
receptor activation also plays a role in nicotine-induced motor
impulsivity by examining the effects of the selective cannabi-
noid CB1 receptor antagonist SR141716A (K i values of 1.8–
12.3 and 514–13200 nM for respectively cannabinoid CB1 and
CB2 receptors; Pertwee, 2010) pretreatment on nicotine-induced
impulsivity in the 5-CSRTT. Two rats had to be removed from
analysis due to technical problems on one of the test days. In
line with previous reports (van Gaalen et al., 2006; Tsutsui-
Kimura et al., 2010; Higgins et al., 2012), acute administration of
0.3mg/kg nicotine increased premature responding (Figure 1A;
F5,65 = 5.20, p= 0.006, ε= 0.54). Although not quite signiﬁcant
as compared to nicotine alone, prior SR141716A administration
completely prevented nicotine-induced increases in premature
responding. Speciﬁcally, detailed analysis showed that 3mg/kg
SR141716A+ nicotine tended (p < 0.1) to lower the amount of
premature responses made as compared to treatment with nico-
tine alone. SR141716A alone did not affect premature responding
at anydose, thereby contrasting an initial studyon the effects of this
compound on premature responding in rats (Pattij et al., 2007a).
This apparent discrepancy is probably related to a ﬂoor effect as
discussed previously (Wiskerke et al., 2011b). As summarized in
Table 1, an additional signiﬁcant treatment effect was observed
for errors of omission (F5,65 = 4.66, p= 0.008, ε= 0.57), with
nicotine decreasing the number of omissions made and 3mg/kg
SR141716A reversing this effect while enhancing the omission
rate when administered alone. Moreover, a signiﬁcant treatment
effect was observed with respect to correct response latencies
(F5,65 = 5.31, p< 0.001), with 3mg/kg SR141716A by itself and
in combination with nicotine increasing latencies as compared
to vehicle and nicotine alone conditions, respectively. No sig-
niﬁcant effects of any treatment combination were observed on
accurate choice (F5,65 = 2.12, p= 0.07), perseverative responding
(F5,65 = 0.67, NS), or feeder latency (F5,65 = 1.09, NS, ε= 0.26).
Interestingly, recent in vivo microdialysis results have suggested
that a cannabinoid-dopamine interaction may be involved in the
behavioral effects of amphetamine, as SR141716A was found to
abolish amphetamine-induceddopamine release speciﬁcally in the
nucleus accumbens shell (Kleijn et al., 2012). To study a putative
cannabinoid-dopamine interaction underlyingmotor impulsivity,
the effects of the selective dopamine transporter inhibitor GBR
12909, alone and in combination with SR141716A, were tested
next in the 5-CSRTT using the rats from the nicotine-SR141716A
experiment. This time one rat had to be excluded due to a tech-
nical failure on one of the test days. As previously shown (van
Gaalen et al., 2006; Baarendse and Vanderschuren, 2012), admin-
istration of GBR 12909 acutely increased premature responding
(Figure 1B; F5,70 = 6.00, p< 0.001, ε= 0.73). Post hoc analyses
showed that prior administration of 1 or 3mg/kg SR141716A did
not affect this GBR 12909 effect, nor did these doses of SR141716A
by themselves affect premature responding. As summarized in
Table 1, signiﬁcant treatment effects were additionally observed
on accurate choice (F5,70 = 3.08, p= 0.01) and errors of omission
(F5,70 = 6.00, p< 0.001), with 3mg/kg SR141716A alone and in
combination with 5mg/kg GBR 12909 slightly reducing the per-
centage of correct choices and increasing the number of omissions
made. Moreover, a signiﬁcant increase in latency to make a correct
responsewas observed after administrationof 3mg/kg SR141716A
by itself (F5,70 = 3.34, p= 0.009). No signiﬁcant effects of any
treatment combination were observed for perseverative responses
(F5,70 = 0.38, NS) or feeder latency (F5,70 = 0.87, NS, ε= 0.28).
NO ROLE FOR ENDOGENOUS OPIOIDS IN REGULATING MOTOR
IMPULSIVITY FOLLOWING A NICOTINE CHALLENGE OR UNDER
CONDITIONS OF HEIGHTENED COGNITIVE LOAD
The ﬁnding that the CB1 receptor plays a critical role in
amphetamine- and nicotine-, but not GBR 12909-induced impul-
sive behavior is intriguing in view of ﬁndings demonstrating that
the impulsivity effects of all three compounds are known to be
mediated by the dopamine system (van Gaalen et al., 2006). A
receptor system that was recently found to modulate dopamine-
induced impulsive responding in the 5-CSRTT is the μ-opioid
receptor system (Wiskerke et al., 2011a). In that study it was
found that blockade of μ-opioid receptors, particularly those
expressed in the nucleus accumbens shell, with either the opioid
receptor antagonist naloxone or the selective μ-opioid recep-
tor antagonist CTAP suppressed amphetamine-induced prema-
ture responding.Moreover, pretreatment with naloxone abolished
GBR 12909-induced impulsive behavior in the 5-CSRTT. These
observations raise the question whether opioid receptors also
mediate nicotine-induced impulsivity. To test this hypothesis, the
effects of nicotine, alone in and in combination with naloxone
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FIGURE 1 | Pretreatment with the CB1 receptor antagonist SR141716A
prevents motor impulsivity induced by the psychostimulant nicotine,
but not the dopamine transporter inhibitor GBR 12909. Effects of acute
administration of 0.3mg/kg nicotine [NIC (A)] or 5mg/kg GBR 12909 [GBR
(B)], alone and in combination with SR141716A (SR), on the mean (±SEM)
number of premature responses made in the 5-CSRTT. In total n=14–15 rats
were included in the analyses. Drug doses are expressed as mg/kg. ∗ p<0.05
versus Vehicle–Vehicle control.
Table 1 | Effects of the psychostimulant nicotine (NIC) and the selective dopamine transporter inhibitor GBR 12909 (GBR), alone and in
combination with the selective CB1 receptor antagonist SR141716A (SR) on measures of attentional function, compulsivity, and motivation in
the 5-CSRTT.
Treatment (mg/kg) Accuracy (%) Perseverative responses Correct response latency (ms) Omissions Feeder latency (ms)
NICOTINE+SR141716A
Vehicle – Vehicle 92.7±1.3 8.5±2.1 570±16 8.2±1.7 1399±81
Vehicle – SR 1 89.4±1.5 10.4±2.6 593±17 11.9±2.6 2027±621
Vehicle – SR 3 89.6±1.9 10.6±3.3 622±23* 14.1±2.4 1534±124
NIC 0.3 – Vehicle 89.2±2.1 8.1±1.9 547±17 4.1±0.7 1351±72
NIC 0.3 – SR 1 87.9±2.1 9.4±2.6 579±18 8.5±1.4 1542±135
NIC 0.3 – SR 3 89.9±2.3 10.4±1.8 591±18# 11.3±2.3# 1769±129
GBR 12909+SR141716A
Vehicle – Vehicle 92.9±1.2 8.9±2.0 570±15 8.0±1.6 1429±81
Vehicle – SR 1 89.5±1.4 10.1±2.4 593±16 11.6±2.4 2048±579
Vehicle – SR 3 88.8±1.8 11.0±3.1 621±21* 13.5±2.3* 1677±184
GBR 5 – Vehicle 89.1±1.9 10.8±1.8 568±14 6.3±1.1 1615±124
GBR 5 – SR 1 89.2±1.8 10.4±1.7 577±19 8.3±1.8 1511±95
GBR 5 – SR 3 86.4±2.6** 10.9±2.2 587±16 13.1±2.2*## 1807±147
In total n=15 and 14 rats were included in the analyses for nicotine-SR141716A and GBR 12909-SR141716A, respectively, and data depict mean±SEM.
*p<0.05 and ** p<0.005 versus respective Vehicle–Vehicle; #p<0.05 and ##p<0.005 versus Nicotine-Vehicle or GBR 12909-Vehicle.
(K i values of ∼0.4, ∼6, and ∼31 nM for respectively μ-, κ-, and
δ-opioid receptors (Goldstein and Naidu, 1989)) were tested in
the 5-CSRTT. Results suggested that endogenous opioids are not
involved in nicotine-induced impulsivity, because pretreatment
with naloxone did not affect nicotine-inducedpremature respond-
ing (Figure 2; F3,45 = 8.18, p< 0.001). As shown in Table 2, the
only other signiﬁcant effect of drug treatment in this experiment
was on perseverative responding (F3,45 = 3.48, p= 0.04, ε= 0.79),
with the combination of 0.3mg/kg nicotine+ 3mg/kg naloxone
signiﬁcantly decreasing the number of perseverative responses
made as compared to vehicle condition. Other behavioral para-
meters were not affected by nicotine or naloxone (accurate choice:
F3,45 = 1.82, NS; correct response latency: F3,45 = 0.49, NS; errors
of omission: F3,45 = 1.34, NS; feeder latency: F3,45 = 0.98, NS).
A possible explanation for the lack of effect of naloxone on
nicotine-induced motor impulsivity would be that the inhibitory
control-promoting effects of naloxone are rate-dependent, and
can only be observed when rats display higher levels of pre-
mature responding. One way to determine rate-dependency of
a compound’s effects on 5-CSRTT behavior is to compare that
compound’s effects under baseline conditions (ITI of 5 s, stimu-
lus duration of 1 s) with its effects under conditions of heightened
cognitive load, e.g., with a lengthened (7 s) ITI duration. The latter
procedural manipulation is known to robustly increase impulsiv-
ity in the 5-CSRTT in a baseline-dependent way (Dalley et al.,
2005, 2007). Via such an experiment, the effects of SR141716A
on premature responding were recently suggested to be rate-
dependent (Wiskerke et al., 2011b). Although the previous ﬁnding
that naloxone effectively suppressed the relatively small increase
in premature responding induced by a challenge injection with
GBR 12909 (Wiskerke et al., 2011a) alreadymade rate-dependency
unlikely to have been a confounding factor in the nicotine-
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naloxone experiment, this explanation was further ruled out by
testing the effects of naloxone under baseline ITI (5 s) and long
ITI (7 s) conditions. Indeed, 1mg/kg naloxone did not affect pre-
mature responding under either condition (Figure 3; Treatment:
F1,15 = 1.50, NS; ITI: F1,15 = 43.17, p< 0.001; Treatment× ITI:
F1,15 = 0.27, NS). In fact, this dose of naloxone did not affect any
behavioral parameter measured (Table 3), while lengthening the
ITI duration did affect accurate choice (Treatment: F1,15 = 2.13,
NS; ITI: F1,15 = 9.91, p= 0.007; Treatment× ITI: F1,15 = 1.00,
NS), perseverative responding (Treatment: F1,15 = 0.55, NS; ITI:
F1,15 = 6.39, p= 0.023; Treatment× ITI: F1,15 = 0.06, NS), and
correct response latencies (Treatment: F1,15 = 0.05, NS; ITI:
F1,15 = 5.52, p= 0.033; Treatment× ITI: F1,15 = 0.22, NS), but
not errors of omission (Treatment: F1,15 = 4.38, p= 0.05; ITI:
F1,15 = 0.00, NS; Treatment× ITI: F1,15 = 0.42, NS) or feeder
latencies (Treatment: F1,15 = 0.07,NS; ITI: F1,15 = 2.04,NS; Treat-
ment× ITI: F1,15 = 1.86,NS). Of note, similar results with respect
to motor impulsivity were obtained for 3mg/kg naloxone in a
separate cohort of rats, although this dose of naloxone tended to
result in additional subtle, non-speciﬁc behavioral effects (data
not shown).
FIGURE 2 | Pretreatment with the opioid receptor antagonist naloxone
does not affect motor impulsivity induced by the psychostimulant
nicotine. Effects of naloxone (NAL) on the mean (±SEM) number of
premature responses made in the 5-CSRTT following a challenge injection
with 0.3mg/kg nicotine (NIC). In total n=16 rats were included in the
analyses. Drug doses are expressed as mg/kg. **p <0.005 versus
Vehicle–Vehicle control.
DISCUSSION
Previous studies have established important roles for the cannabi-
noid, dopamine, and opioid systems in regulating the effects of the
psychostimulant drug amphetamine onmotor impulsivity asmea-
sured in the 5-CSRTT (Cole and Robbins, 1987, 1989; van Gaalen
et al., 2006;Wiskerke et al., 2011a,b). In the present study,we exam-
ined whether this also holds true for the psychostimulant nicotine.
Results showed that the cannabinoid CB1 receptor antagonist
SR141716A reduced premature responding following a challenge
with nicotine, but not the dopamine transporter inhibitor GBR
12909. In contrast to SR141716A, the opioid receptor antagonist
naloxone did not affectmotor impulsivity induced by nicotine,nor
did pretreatment with this antagonist affect premature responding
under baseline (5 s) or lengthened (7 s) ITI conditions. Together,
these ﬁndings indicate that endogenous cannabinoids,but not opi-
oids,mediate nicotine-induced inhibitory control deﬁcits, thereby
extending the current knowledge on the role of cannabinoids and
opioids in nicotine-induced behaviors (Berrendero et al., 2010;
Hadjiconstantinou and Neff, 2011; Serrano and Parsons, 2011).
The current data are only partly in line with previous ﬁndings
on amphetamine-induced impulsivity (Wiskerke et al., 2011a,b),
suggesting that distinct mechanisms underlie the effects of drugs
of abuse. Furthermore, the current data underscore the complex
interplay between the cannabinoid, dopamine, and opioid systems
in regulating motor impulsivity.
CANNABINOID-DOPAMINE INTERACTIONS UNDERLYING MOTOR
IMPULSIVITY REVISITED
Endogenous cannabinoid CB1 receptor activity appears to facili-
tate motor impulsivity as measured in the 5-CSRTT, while exoge-
nous CB1 receptor agonists are ineffective in this respect (Pattij
et al., 2007a; de Bruin et al., 2011; Wiskerke et al., 2011b). Simi-
larly, the importance of dopamine signaling in regulating motor
impulsivity is well known (Pattij and Vanderschuren, 2008; Dal-
ley et al., 2011; Winstanley, 2011). Based on a large literature
on reciprocal cannabinoid-dopamine interactions in the brain
(Tanda et al., 1997; Solinas et al., 2008; El Khoury et al., 2012)
it could be speculated that cannabinoids and dopamine commu-
nally regulate impulsive responses. In support of this, previous
studies using experimental conditions similar to those of the cur-
rent study have demonstrated SR141716A-mediated attenuation
of amphetamine-induced premature responding in the 5-CSRTT
(Wiskerke et al., 2011b) and dopamine release in the nucleus
accumbens shell, but not the nucleus accumbens core or medial
Table 2 | Effects of the opioid receptor antagonist naloxone (NAL) on measures of attentional function, compulsivity, and motivation in the
5-CSRTT following a challenge injection with the psychostimulant nicotine (NIC).
Treatment (mg/kg) Accuracy (%) Perseverative responses Correct response latency (ms) Omissions Feeder latency (ms)
Vehicle – Vehicle 85.4±1.5 12.3±3.5 589±21 8.8±0.7 1805±181
NIC 0.3 – Vehicle 83.3±1.3 7.3±2.4 580±15 6.8±1.0 1676±193
NIC 0.3 – NAL 1 83.7±1.5 9.8±1.7 574±16 8.6±2.2 1680±131
NIC 0.3 – NAL 3 81.6±1.5 4.6±1.1* 588±18 10.9±1.8 1508±92
In total n=16 rats were included in the analyses, and data depict mean±SEM.
*p<0.05 versus Vehicle–Vehicle control.
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FIGURE 3 | Pretreatment with the opioid receptor antagonist naloxone
does not affect motor impulsivity under long intertrial interval (ITI)
conditions. Effects of naloxone (NAL) on the mean (±SEM) number of
premature responses made in the 5-CSRTT under conditions of normal or
lengthened ITI. In total n=16 rats were included in the analyses. Drug doses
are expressed as mg/kg. **p<0.005 versus respective Vehicle control.
Table 3 | Effects of the opioid receptor antagonist naloxone (NAL) on measures of attentional function, compulsivity, and motivation in the
5-CSRTT under conditions of normal or lengthened intertrial interval (ITI).
Treatment (mg/kg) ITI (s) Accuracy (%) Perseverative responses Correct response latency (ms) Omissions Feeder latency (ms)
Vehicle 5 83.9±2.4 11.0±2.1 626±23 8.8±1.8 1706±208
NAL 1 5 86.7±2.6 10.3±2.6 632±20 14.8±3.1 2042±405
Vehicle 7 80.7±2.7+ 6.6±1.7+ 602±23 10.3±1.8 1686±259
NAL 1 7 81.0±2.5+ 5.3±1.2+ 591±17 13.4±2.2 1476±86
In total n=16 rats were included in the analyses, and data depict mean±SEM.
+p<0.05 versus respective ITI=5 s control.
prefrontal cortex (Kleijn et al., 2012). Because nicotine effects in
the 5-CSRTT have been reported to be dopamine D2 receptor-
dependent (van Gaalen et al., 2006), the current results showing
that SR141716A prevents nicotine-induced premature responding
are in line with the existence of a cannabinoid-dopamine inter-
action. The unexpected ﬁnding that SR141716A did not affect
GBR 12909-induced premature responding, however, is not. The
key to the cannabinoid-dopamine puzzle may be in the anatom-
ical locus of the CB1 receptors involved in regulating 5-CSRTT
behavior. It could be argued that the cannabinoid-dopamine inter-
action modulating motor impulsivity occurs at the cortical level.
There, in contrast to nicotine and amphetamine (Nisell et al.,
1996, 1997; Marshall et al., 1997; Dalley et al., 2002b; Kleijn et al.,
2012), GBR 12909 does not robustly increase dopamine levels
due to the low expression of the dopamine transporter in cor-
tical areas (Elsworth et al., 1993; Freed et al., 1995; Sesack et al.,
1998; Weikop et al., 2007). There is general consensus regarding
the importance of the medial prefrontal cortex, and particularly
the infralimbic cortex, in regulating motor impulsivity (Winstan-
ley et al., 2006; Pattij and Vanderschuren, 2008; Dalley et al.,
2011), and the effects of nicotine thereon (Tsutsui-Kimura et al.,
2010). The role of dopamine in this brain area with respect to
(drug-induced) motor impulsivity, however, has not been stud-
ied extensively. Available data actually suggest an important role
for dopamine signaling within the nucleus accumbens rather than
the medial prefrontal cortex in driving impulsive responding in
the 5-CSRTT (Cole and Robbins, 1987, 1989; Puumala and Sirvio,
1998; Dalley et al., 2002a,b; Pattij et al., 2007b; Diergaarde et al.,
2008). One recent study, however, suggests that dopamine sig-
naling within another cortical brain region, the orbital frontal
cortex, may be important in this respect as well (Winstanley
et al., 2010b). Future studies using intracranial infusions should
elucidate this issue.
It should be noted that psychostimulants such as ampheta-
mine and nicotine can (in)directly affect many neurotransmit-
ter systems including the norepinephric, serotonergic, and glu-
tamatergic systems (McGinty, 1999; Rothman and Baumann,
2003; Berrendero et al., 2010). As none of these neurotransmitter
systems were studied here, impulsivity-related, psychostimulant-
induced release of endogenous cannabinoids may not require
dopamine transmission. For instance, metabotropic glutamate
receptor (mGluRs) subtypes 2/3 and 5 have been implicated in the
neural mechanisms underlying premature responding (Semenova
and Markou, 2007; Liu et al., 2008; Counotte et al., 2011) as well
as amphetamine- and nicotine-induced behaviors (Olive, 2009;
Berrendero et al., 2010). Moreover, both mGluR2/3 and mGluR5
receptors have previously been reported to mediate the effects of
CB1 receptor antagonists on amphetamine- and cocaine-induced
behaviors (Xi et al., 2006; Tzavara et al., 2009; Ramiro-Fuentes
et al., 2010).
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INTERACTIONS BETWEEN THE DOPAMINE AND μ-OPIOID RECEPTOR
SYSTEMS ONLY MEDIATE MOTOR IMPULSIVITY UNDER SPECIFIC
CONDITIONS
The endogenous opioid system, and particularly the μ-opioid
receptor, is another neurotransmitter system that has previously
been linked to impulsive behavior in humans and rodents (Kieres
et al., 2004;Mitchell et al., 2007; Love et al., 2009; Pattij et al., 2009).
The μ-opioid receptor system is known to interact with both the
dopamine (Di Chiara and Imperato, 1988; Hurd and Herkenham,
1992; Spanagel et al., 1992) and cannabinoid systems (Robledo
et al., 2008; Parolaro et al., 2010).With regard tomotor impulsivity
as measured in the 5-CSRTT, it has previously been demonstrated
that acute stimulation of μ-opioid receptors, speciﬁcally those
in the nucleus accumbens shell, increases premature respond-
ing, whereasμ-opioid receptor antagonists reducemorphine- and
amphetamine-induced premature responding (Wiskerke et al.,
2011a). In that study, naloxone was also found to abolish GBR
12909-induced motor impulsivity, suggesting a dopamine-opioid
link in regulating this type of impulsive behavior. The lack of
effect of naloxone on nicotine-induced premature responding
observed here, however, indicates that endogenous opioid systems
do notmediate all dopamine-dependent forms of motor impulsiv-
ity. In view of previous ﬁndings regarding amphetamine-induced
impulsivity (Cole and Robbins, 1987, 1989; Pattij et al., 2007b;
Wiskerke et al., 2011a), the dopamine-opioid interaction may well
be restricted to themesolimbic dopamine pathway. Systemic nico-
tine administration acutely activates both the mesolimbic and
mesocortical dopaminergic system (Nisell et al., 1996, 1997; Mar-
shall et al., 1997). Unfortunately, it is as yet unknown which of
those effects is relevant for display of impulsive behavior. More-
over, in vivo microdialysis studies thus far have only examined
the role of μ-opioid receptors in amphetamine- and nicotine-
induced changes in mesolimbic dopamine release (Hooks et al.,
1992; Maisonneuve and Glick, 1999; Schad et al., 2002; Berren-
dero et al., 2005). Alternatively, considering that all drugs of abuse
have distinct effects on dopamine transmission (Sulzer, 2011), the
way the dopaminergic system is activated (release quantity, pha-
sic or tonic activity, burst or spike ﬁring, etc.) may determine
whether endogenous opioid systems are recruited to modulate
premature responding. In this respect it is of interest that systemic
challenges with psychostimulant drugs like GBR 12909 and par-
ticularly amphetamine havemuch stronger effects on extracellular
dopamine levels as compared to nicotine (Di Chiara and Imper-
ato, 1988; Leggio et al., 2009). Furthermore, since no selective
μ-, δ-, or κ-opioid receptor antagonists were tested in this study,
it cannot be ruled out that the observed nicotine effects result
from δ- and/or κ-opioid receptor activation in addition to that of
μ-opioid receptors since all endogenous opioid peptide systems
are activated following an acute challenge with nicotine (Berren-
dero et al., 2010; Hadjiconstantinou and Neff, 2011). Although
naloxone at low doses preferentially blocks μ-opioid receptors
(Goldstein and Naidu, 1989; Eguchi, 2004), additional effects on
δ- and/or κ-opioid receptors may have resulted in the absence
of an overall effect on nicotine-induced premature responding.
On the other hand, amphetamine also activates all endogenous
opioid peptide systems (Hurd and Herkenham, 1992; Wang and
McGinty, 1995; Olive et al., 2001), but only μ-opioid receptors
seem to be involved in amphetamine-induced motor impulsivity
(Wiskerke et al., 2011a). Clearly, more research is required to elu-
cidate the conditions under which dopamine-opioid interactions
are recruited to modulate motor impulsivity.
A RATE-DEPENDENT ROLE FOR CANNABINOID CB1 RECEPTORS, BUT
NOT μ-OPIOID RECEPTORS, IN REGULATING MOTOR IMPULSIVITY
UNDER DRUG-FREE CONDITIONS
In addition to the role of cannabinoids and opioids in drug-
induced motor impulsivity, we also evaluated their involvement
in impulsive responding under drug-free conditions. The obser-
vation that naloxone did not affect premature responding under
either high impulsivity (ITI= 7 s) or baseline (ITI= 5 s) condi-
tions indicates that μ-opioid receptors are not involved in regu-
lating motor impulsivity under non-drug (“healthy”) conditions.
Instead, this neurotransmitter system can apparently be usurped
by speciﬁc drugs of abuse such as amphetamine and opiates to
increase motor impulsivity. In contrast, cannabinoid CB1 recep-
tor antagonists have previously been shown to improve inhibitory
control under drug-free conditions (Pattij et al., 2007a; de Bruin
et al., 2011), with the effects becoming more apparent under con-
ditions favoring higher levels of premature responding (Wiskerke
et al., 2011b). Similarly, the dopamine D2 receptor antagonist
eticlopride may attenuate premature responding under 7 s, but
not 5 s ITI conditions (Wiskerke and Pattij, unpublished obser-
vations). Thus, the anti-impulsivity effects of cannabinoid CB1
and dopamine D2 receptor antagonists may be rate-dependent
and only be revealed under conditions of heightened cognitive
load/inhibitory control demands, e.g., when the ITI duration is
lengthened or following drug-induced increments in dopamine
signaling.
Finally, it might be argued that effects on premature respond-
ing induced by drugs targeting the cannabinoid, dopaminergic,
or opioid system are secondary to changes in other behav-
ioral/cognitive processes. Several of the compounds used in
previous studies from our laboratory to elucidate the role
of cannabinoids, dopamine, and opioids in motor impulsiv-
ity also affected other behavioral parameters in the 5-CSRTT,
particularly at higher doses (van Gaalen et al., 2006; Pattij
et al., 2007a,b, 2009; Wiskerke et al., 2011a,b). Some of these
parameters may reﬂect indices of food motivation, somato-
motor activity, and/or timing behavior (Robbins, 2002). Sim-
ilarly, in the current study particularly 3mg/kg SR141716A
increased omission rate and lengthened correct response laten-
cies. Unlike drug-induced changes in motor impulsivity though,
the reported drug effects on other behavioral parameters in the
5-CSRTT are usually modest and inconsistent between experi-
ments, and donot correlatewith the observed effects on premature
responding.
CONCLUSION
This study did not fully elucidate the role of the endogenous
cannabinoid, dopamine, and opioid systems in the regulation
motor impulsivity, and the effects of drugs of abuse thereon.
Nevertheless, the current data do underscore that all three neu-
rotransmitter systems play an important role in this respect. Most
likely, the cannabinoid, dopamine, and opioid systems interact
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in the regulation of (drug-induced) motor impulsivity. How-
ever, similar to what has previously been concluded for other
reward-related behaviors such as social play behavior (Trezza et al.,
2010), the current data suggest that this interaction is not simply
triangular with reciprocal interactions between all three neuro-
transmitters. We hypothesize that the observed complexity arises
from(1) the fact that two (indirectly heavily interacting) dopamin-
ergic systems, the mesolimbic and mesocortical systems, subserve
motor impulsivity, and (2) the fact that all drugs of abuse usurp
distinct mechanisms to induce dopamine release, resulting in
regionally (at the brain region as well as the synaptic level) and
quantitatively quite distinct patterns of dopamine release. Thus,
the spatial, temporal, and quantitative properties of impulsivity-
related dopamine release might determine the extent to which
the endogenous cannabinoid and opioid systems are recruited.
Future studies employing intracranial infusions are required to
start elucidating this issue. Froma clinical perspective, it is of inter-
est that genotype for and the expression/availability of cannabi-
noid CB1, dopamine D2, and μ-opioid receptors may determine
one’s level of impulsivity and vulnerability to impulsivity-related
disorders such as Attention-Deﬁcit/Hyperactivity Disorder and
substance abuse (Dalley et al., 2007; Ehlers et al., 2007; Cen-
tonze et al., 2009; Love et al., 2009; Buckholtz et al., 2010). Thus,
the “state” of a patient’s endogenous cannabinoid, dopamine,
and opioid neurotransmitter systems might determine to what
type of pharmacotherapy the patient will respond best. Impor-
tantly, impulsive behavior is thought to constitute several, largely
independent behavioral modalities (Evenden, 1999; Winstanley
et al., 2006; Pattij and Vanderschuren, 2008; Broos et al., 2012).
Therefore, future research will also have to determine whether
the current results on motor impulsivity generalize to other
aspects of impulsivity. Similarly, previous studies have indicated
that the effects of SR141716A and eticlopride, but not nalox-
one, on amphetamine-induced impulsivity generalize to impul-
sive choice, i.e., an intolerance to delayed gratiﬁcation or delay
aversion.
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